<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>334</serviceExecutionTime><Drug id="85711"><DrugName>selegiline hydrochloride (orally disintegrating tablet, Parkinsons disease), FP Pharmaceutical</DrugName><DrugNamesKey><Name id="42758810">selegiline</Name><Name id="42758811">selegiline hydrochloride</Name></DrugNamesKey><DrugSynonyms><Name><Value>selegiline</Value><Types><Type>USAN</Type><Type>BANN</Type><Type>INN</Type></Types></Name><Name><Value>selegiline hydrochloride</Value><Types><Type>USAN</Type></Types></Name><Name><Value>FPF-1100NW</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>FP-OD Tablet 2.5</Value></Name><Name><Value>selegiline (orally disintegrating tablet, Parkinsons disease), FP Pharmaceutical</Value></Name><Name><Value>FP OD Tablets 2.5</Value></Name><Name><Value>selegiline hydrochloride (orally disintegrating tablet, Parkinsons disease), FP Pharmaceutical</Value></Name><Name><Value>14611-51-9</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>14611-52-0</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1082974">FP Pharmaceutical Corp</CompanyOriginator><CompaniesPrimary><Company id="1082974">FP Pharmaceutical Corp</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1082974" type="Company"><TargetEntity id="5039717577" type="organizationId">FP Pharmaceutical Corp</TargetEntity></SourceEntity><SourceEntity id="255" type="ciIndication"><TargetEntity id="G20" type="ICD10"/><TargetEntity id="10061536" type="MEDDRA"/><TargetEntity id="D010300" type="MeSH"/><TargetEntity id="-342157116" type="omicsDisease"/><TargetEntity id="127" type="siCondition"/></SourceEntity><SourceEntity id="255" type="Action"><TargetEntity id="450" type="Mechanism">MAO-B Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01274" type="ciTarget"><TargetEntity id="56692312941293" type="siTarget">Amine oxidase [flavin-containing] B</TargetEntity><TargetEntity id="6224" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Parkinsons disease - Japan - Jul-2007</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="255">Parkinsons disease</Indication></IndicationsPrimary><ActionsPrimary><Action id="255">MAO B inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2947">Antiparkinsonian</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="902">Orally disintegrating tablet</Technology></Technologies><EphmraCodes><Ephmra><Code>N3A</Code><Name>ANTI-EPILEPTICS</Name></Ephmra></EphmraCodes><LastModificationDate>2015-12-03T11:15:19.000Z</LastModificationDate><ChangeDateLast>2018-09-11T00:00:00.000Z</ChangeDateLast><AddedDate>2013-06-13T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1082974" linkType="Company"&gt;FP Pharmaceutical&lt;/ulink&gt; has developed and launched FP-1100NW (FP OD Tablets 2.5; FP-OD Tablet 2.5), an orally disintegrating tablet formulation of selegiline hydrochloride, for use in combination therapy with levodopa for the treatment of Parkinson's disease. The product was launched in Japan in July 2007  [&lt;ulink linkID="1437267" linkType="Reference"&gt;1437267&lt;/ulink&gt;]. The company is also developing the product as a monotherapy for the potential treatment of early-stage Parkinson's disease [&lt;ulink linkID="1434914" linkType="Reference"&gt;1434914&lt;/ulink&gt;]; in November 2015, the Ministry of Health, Labour and Welfare's First Committee on New Drugs, Pharmaceutical Affairs and Food Sanitation Council recommended approval of selegiline monotherapy for Parkinson's disease [&lt;ulink linkID="1716855" linkType="Reference"&gt;1716855&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In March 2007, the product was approved in Japan for use in combination with levodopa in Parkinson's disease. In July 2007, the product was launched [&lt;ulink linkID="1437267" linkType="Reference"&gt;1437267&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2015, the Ministry of Health, Labour and Welfare's First Committee on New Drugs, Pharmaceutical Affairs and Food Sanitation Council recommended approval of selegiline monotherapy for Parkinson's disease [&lt;ulink linkID="1716855" linkType="Reference"&gt;1716855&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In April 2012, a multicenter, open trial (&lt;ulink linkID="138156" linkType="Protocol"&gt;JapicCTI-122000&lt;/ulink&gt;) began to study safety and efficacy of long-term administration with FP-1100NW monotherapy in early-stage Parkinson's disease patients (estimated n = 130) who had completed the phase III trial. The study was ongoing in June 2013 and was expected to complete in July 2014 [&lt;ulink linkID="1434927" linkType="Reference"&gt;1434927&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2012, a multicenter, randomized, double-blind, placebo-controlled, phase III trial (&lt;ulink linkID="138155" linkType="Protocol"&gt;JapicCTI-121954&lt;/ulink&gt;) was initiated to study single administration of FP-1100NW in early-stage Parkinson's disease patients (estimated n = 280) in Japan. The primary endpoint would be total score on Japanese UPDRS parts 1, 2, 3 rating scales. In February 2013, the trial was expected to complete in September 2013 [&lt;ulink linkID="1434914" linkType="Reference"&gt;1434914&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2009, a multicenter, randomized, double-blind, placebo-controlled, phase II trial (&lt;ulink linkID="127683" linkType="Protocol"&gt;JapicCTI-101020&lt;/ulink&gt;) began in Japan to evaluate the safety and effect of single administration of FP-1100NW on initial symptoms in patients (n = 90) with early Parkinson's disease. The trial completed in February 2011 [&lt;ulink linkID="1415795" linkType="Reference"&gt;1415795&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1082974">FP Pharmaceutical Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="255">Parkinsons disease</Indication><StatusDate>2007-07-25T00:00:00.000Z</StatusDate><Source id="1437267" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1082974">FP Pharmaceutical Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="255">Parkinsons disease</Indication><StatusDate>2007-03-15T00:00:00.000Z</StatusDate><Source id="1437267" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01274"><Name>MAO B</Name><SwissprotNumbers><Swissprot>P19643</Swissprot><Swissprot>P27338</Swissprot><Swissprot>P56560</Swissprot><Swissprot>P58028</Swissprot><Swissprot>Q5RE98</Swissprot><Swissprot>Q6PLK3</Swissprot><Swissprot>Q7YRB7</Swissprot><Swissprot>Q8BW75</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1716855" linkType="reference" linkID="1716855"&gt;1716855&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>C[C@H](Cc1ccccc1)N(C)CC#C</Smiles><Smiles>C[C@H](Cc1ccccc1)N(C)CC#C.Cl</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="2544113" number="JP-2007015966" title="Orally disintegrating tablet"/><PatentFamily id="3201735" number="WO-2016088111" title="Arylalkylamine compounds for use in the prevention or treatment of cancer"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fujimoto Pharmaceutical Corp" id="16221"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Semmelweis University" id="25632"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>